Richard Lafayette

14PUBLICATIONS
41CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Health and ecological risk assessmentImmunogenetics (incl. genetic immunology)Cardiology (incl. cardiovascular diseases)Characterisation of biological macromolecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jun 11, 2026
Humoral Response to COVID-19 Vaccines and Infection during Sibeprenlimab Treatment of IgA Nephropathy: Data from the ENVISION Trial.

|Feb 01, 2026
A plain language summary: long-term safety and effectiveness of atacicept in individuals with IgA nephropathy.

Jonathan Barratt, Kelly Chen, Richard Lafayette

|Oct 09, 2025
TESTING for the Best Biomarker in IgA Nephropathy.

Richard A Lafayette

|Aug 22, 2025
Authors' Reply: Ravulizumab in IgA Nephropathy: A Promising Step Toward Disease Modification?

Jonathan Barratt, Youssef M K Farag, Min Yee

|Mar 27, 2025
Expert Discussion on Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Challenges and Considerations.

Richard A Lafayette, Vivek Charu, Richard J Glassock

|Mar 26, 2025
Authors' Reply: Complement Inhibition Therapy in IgA Nephropathy: Total or Selective Inhibition?

Jonathan Barratt, Katherine Garlo, Andreas Kateifides

Pageof 3

Frequent Collaborators

6 joint publications

Jonathan Barratt

2 joint publications

Vivek Charu

2 joint publications

Andrew S Bomback

2 joint publications

Leal C Herlitz